LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 122

Search options

  1. Article ; Online: Modeling Genomic Screening in Newborns.

    Lu, Christine Y / McMahon, Pamela M / Wu, Ann Chen

    JAMA pediatrics

    2022  Volume 176, Issue 4, Page(s) 344–346

    MeSH term(s) Humans ; Infant, Newborn ; Neonatal Screening
    Language English
    Publishing date 2022-01-23
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2701223-2
    ISSN 2168-6211 ; 2168-6203
    ISSN (online) 2168-6211
    ISSN 2168-6203
    DOI 10.1001/jamapediatrics.2021.5798
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: The association of varying treatment thresholds of mepolizumab on asthma exacerbations in adults.

    Davis, Jaclyn / McMahon, Pamela M / Simon, Andrew / Haffenreffer, Katherine / Jamal-Allial, Aziza / McMahill-Walraven, Cheryl N / Kline, Anne Marie / Brown, Jeffrey S / Van Dyke, Melissa K / Jakes, Rupert W / Wu, Ann Chen

    The Journal of asthma : official journal of the Association for the Care of Asthma

    2023  Volume 60, Issue 12, Page(s) 2198–2206

    Abstract: Background: ...

    Abstract Background:
    MeSH term(s) Adult ; Humans ; Adolescent ; Asthma/epidemiology ; Anti-Asthmatic Agents ; Adrenal Cortex Hormones/therapeutic use ; Biological Products/therapeutic use
    Chemical Substances mepolizumab (90Z2UF0E52) ; Anti-Asthmatic Agents ; Adrenal Cortex Hormones ; Biological Products
    Language English
    Publishing date 2023-06-27
    Publishing country England
    Document type Observational Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 603816-5
    ISSN 1532-4303 ; 0277-0903
    ISSN (online) 1532-4303
    ISSN 0277-0903
    DOI 10.1080/02770903.2023.2228900
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Association of Alopecia Areata With Attention-Deficit/Hyperactivity Disorder Stimulant Medication: A Case-Control Study.

    Meaux, Tyson A / McMahon, Pamela M / Jones, Glenn N / Bush, Amelia E / Kennedy, Jaren J / Poche, George William

    The Ochsner journal

    2021  Volume 21, Issue 2, Page(s) 139–142

    Abstract: Background: ...

    Abstract Background:
    Language English
    Publishing date 2021-06-18
    Publishing country United States
    Document type Journal Article
    ISSN 1524-5012
    ISSN 1524-5012
    DOI 10.31486/toj.20.0025
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Benefits, harms, and costs of newborn genetic screening for hypertrophic cardiomyopathy: Estimates from the PreEMPT model.

    Christensen, Kurt D / McMahon, Pamela M / Galbraith, Lauren N / Yeh, Jennifer M / Stout, Natasha K / Lu, Christine Y / Stein, Sarah / Zhao, Maryann / Hylind, Robyn J / Wu, Ann Chen

    Genetics in medicine : official journal of the American College of Medical Genetics

    2023  Volume 25, Issue 4, Page(s) 100797

    Abstract: Purpose: Population newborn genetic screening for hypertrophic cardiomyopathy (HCM) is feasible, however its benefits, harms, and cost-effectiveness are uncertain.: Methods: We developed a microsimulation model to simulate a US birth cohort of 3.7 ... ...

    Abstract Purpose: Population newborn genetic screening for hypertrophic cardiomyopathy (HCM) is feasible, however its benefits, harms, and cost-effectiveness are uncertain.
    Methods: We developed a microsimulation model to simulate a US birth cohort of 3.7 million newborns. Those identified with pathogenic/likely pathogenic variants associated with increased risk of HCM underwent surveillance and recommended treatment, whereas in usual care, individuals with family histories of HCM underwent surveillance.
    Results: In a cohort of 3.7 million newborns, newborn genetic screening would reduce HCM-related deaths through age 20 years by 44 (95% uncertainty interval [UI] = 10-103) however increase the numbers of children undergoing surveillance by 8127 (95% UI = 6308-9664). Compared with usual care, newborn genetic screening costs $267,000 per life year saved (95% UI, $106,000 to $919,000 per life year saved).
    Conclusion: Newborn genetic screening for HCM could prevent deaths but at a high cost and would require many healthy children to undergo surveillance. This study shows how modeling can provide insights into the tradeoffs between benefits and costs that will need to be considered as newborn genetic screening is more widely adopted.
    MeSH term(s) Child ; Humans ; Infant, Newborn ; Young Adult ; Adult ; Genetic Testing ; Cardiomyopathy, Hypertrophic/diagnosis ; Cardiomyopathy, Hypertrophic/genetics ; Neonatal Screening ; Cost-Effectiveness Analysis
    Chemical Substances preempt
    Language English
    Publishing date 2023-01-31
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 1455352-1
    ISSN 1530-0366 ; 1098-3600
    ISSN (online) 1530-0366
    ISSN 1098-3600
    DOI 10.1016/j.gim.2023.100797
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: An Atypical Case of

    Mathews, Dionna M / Vance, Katie M / McMahon, Pamela M / Boston, Catherine / Bolton, Michael T

    Case reports in pediatrics

    2018  Volume 2018, Page(s) 2750275

    Abstract: Bartonella ... ...

    Abstract Bartonella henselae
    Language English
    Publishing date 2018-04-05
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2659094-3
    ISSN 2090-6811 ; 2090-6803
    ISSN (online) 2090-6811
    ISSN 2090-6803
    DOI 10.1155/2018/2750275
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Clinical Decision Support for Hypertension Management in Chronic Kidney Disease: A Randomized Clinical Trial.

    Samal, Lipika / Kilgallon, John L / Lipsitz, Stuart / Baer, Heather J / McCoy, Allison / Gannon, Michael / Noonan, Sarah / Dunk, Ryan / Chen, Sarah W / Chay, Weng Ian / Fay, Richard / Garabedian, Pamela M / Wu, Edward / Wien, Matthew / Blecker, Saul / Salmasian, Hojjat / Bonventre, Joseph V / McMahon, Gearoid M / Bates, David W /
    Waikar, Sushrut S / Linder, Jeffrey A / Wright, Adam / Dykes, Patricia

    JAMA internal medicine

    2024  

    Abstract: Importance: Chronic kidney disease (CKD) affects 37 million adults in the United States, and for patients with CKD, hypertension is a key risk factor for adverse outcomes, such as kidney failure, cardiovascular events, and death.: Objective: To ... ...

    Abstract Importance: Chronic kidney disease (CKD) affects 37 million adults in the United States, and for patients with CKD, hypertension is a key risk factor for adverse outcomes, such as kidney failure, cardiovascular events, and death.
    Objective: To evaluate a computerized clinical decision support (CDS) system for the management of uncontrolled hypertension in patients with CKD.
    Design, setting, and participants: This multiclinic, randomized clinical trial randomized primary care practitioners (PCPs) at a primary care network, including 15 hospital-based, ambulatory, and community health center-based clinics, through a stratified, matched-pair randomization approach February 2021 to February 2022. All adult patients with a visit to a PCP in the last 2 years were eligible and those with evidence of CKD and hypertension were included.
    Intervention: The intervention consisted of a CDS system based on behavioral economic principles and human-centered design methods that delivered tailored, evidence-based recommendations, including initiation or titration of renin-angiotensin-aldosterone system inhibitors. The patients in the control group received usual care from PCPs with the CDS system operating in silent mode.
    Main outcomes and measures: The primary outcome was the change in mean systolic blood pressure (SBP) between baseline and 180 days compared between groups. The primary analysis was a repeated measures linear mixed model, using SBP at baseline, 90 days, and 180 days in an intention-to-treat repeated measures model to account for missing data. Secondary outcomes included blood pressure (BP) control and outcomes such as percentage of patients who received an action that aligned with the CDS recommendations.
    Results: The study included 174 PCPs and 2026 patients (mean [SD] age, 75.3 [0.3] years; 1223 [60.4%] female; mean [SD] SBP at baseline, 154.0 [14.3] mm Hg), with 87 PCPs and 1029 patients randomized to the intervention and 87 PCPs and 997 patients randomized to usual care. Overall, 1714 patients (84.6%) were treated for hypertension at baseline. There were 1623 patients (80.1%) with an SBP measurement at 180 days. From the linear mixed model, there was a statistically significant difference in mean SBP change in the intervention group compared with the usual care group (change, -14.6 [95% CI, -13.1 to -16.0] mm Hg vs -11.7 [-10.2 to -13.1] mm Hg; P = .005). There was no difference in the percentage of patients who achieved BP control in the intervention group compared with the control group (50.4% [95% CI, 46.5% to 54.3%] vs 47.1% [95% CI, 43.3% to 51.0%]). More patients received an action aligned with the CDS recommendations in the intervention group than in the usual care group (49.9% [95% CI, 45.1% to 54.8%] vs 34.6% [95% CI, 29.8% to 39.4%]; P < .001).
    Conclusions and relevance: These findings suggest that implementing this computerized CDS system could lead to improved management of uncontrolled hypertension and potentially improved clinical outcomes at the population level for patients with CKD.
    Trial registration: ClinicalTrials.gov Identifier: NCT03679247.
    Language English
    Publishing date 2024-03-11
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2699338-7
    ISSN 2168-6114 ; 2168-6106
    ISSN (online) 2168-6114
    ISSN 2168-6106
    DOI 10.1001/jamainternmed.2023.8315
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research.

    Kunst, Natalia / Stout, Natasha K / O'Brien, Grace / Christensen, Kurt D / McMahon, Pamela M / Wu, Ann Chen / Diller, Lisa R / Yeh, Jennifer M

    Journal of the National Cancer Institute

    2022  Volume 114, Issue 5, Page(s) 722–731

    Abstract: Background: Identification of children and infants with Li-Fraumeni syndrome prompts tumor surveillance and allows potential early cancer detection. We assessed the clinical benefits and cost-effectiveness of population-wide newborn screening for TP53 ... ...

    Abstract Background: Identification of children and infants with Li-Fraumeni syndrome prompts tumor surveillance and allows potential early cancer detection. We assessed the clinical benefits and cost-effectiveness of population-wide newborn screening for TP53 variants (TP53-NBS).
    Methods: We simulated the impact of TP53-NBS using data regarding TP53-associated pediatric cancers and pathogenic or likely pathogenic (P/LP) TP53 variants from Surveillance, Epidemiology, and End Results; ClinVar and gnomAD; and clinical studies. We simulated an annual US birth cohort under usual care and TP53-NBS and estimated clinical benefits, life-years, and costs associated with usual care and TP53-NBS.
    Results: Under usual care, of 4 million newborns, 608 (uncertainty interval [UI] = 581-636) individuals would develop TP53-associated cancers before age 20 years. Under TP53-NBS, 894 individuals would have P/LP TP53 variants detected. These individuals would undergo routine surveillance after detection of P/LP TP53 variants decreasing the number of cancer-related deaths by 7.2% (UI = 4.0%-12.1%) overall via early malignancy detection. Compared with usual care, TP53-NBS had an incremental cost-effectiveness ratio of $106 009 per life-year gained. Probabilistic analysis estimated a 40% probability that TP53-NBS would be cost-effective given a $100 000 per life-year gained willingness-to-pay threshold. Using this threshold, a value of information analysis found that additional research on the prevalence of TP53 variants among rhabdomyosarcoma cases would resolve most of the decision uncertainty, resulting in an expected benefit of 349 life-years gained (or $36.6 million).
    Conclusions: We found that TP53-NBS could be cost-effective; however, our findings suggest that further research is needed to reduce the uncertainty in the potential health outcomes and costs associated with TP53-NBS.
    MeSH term(s) Child ; Cost-Benefit Analysis ; Early Detection of Cancer ; Germ Cells ; Humans ; Infant ; Infant, Newborn ; Li-Fraumeni Syndrome/diagnosis ; Li-Fraumeni Syndrome/epidemiology ; Li-Fraumeni Syndrome/genetics ; Neonatal Screening ; Tumor Suppressor Protein p53/genetics ; Young Adult
    Chemical Substances TP53 protein, human ; Tumor Suppressor Protein p53
    Language English
    Publishing date 2022-01-18
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2992-0
    ISSN 1460-2105 ; 0027-8874 ; 0198-0157
    ISSN (online) 1460-2105
    ISSN 0027-8874 ; 0198-0157
    DOI 10.1093/jnci/djac013
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Characteristics of new adult users of mepolizumab with asthma in the USA.

    Wu, Ann Chen / McMahon, Pamela M / Welch, Emily / McMahill-Walraven, Cheryl N / Jamal-Allial, Aziza / Gallagher, Mia / Zhang, Tancy / Draper, Christine / Kline, Anne Marie / Koerner, Leslie / Brown, Jeffrey S / Van Dyke, Melissa K

    BMJ open respiratory research

    2021  Volume 8, Issue 1

    Abstract: Background: In the USA, over 25 million people have asthma; 5%-10% of cases are severe. Mepolizumab (Nucala) is an interleukin-5 antagonist monoclonal antibody; it was approved by the FDA in 2015 as add-on maintenance treatment of severe asthma for ... ...

    Abstract Background: In the USA, over 25 million people have asthma; 5%-10% of cases are severe. Mepolizumab (Nucala) is an interleukin-5 antagonist monoclonal antibody; it was approved by the FDA in 2015 as add-on maintenance treatment of severe asthma for patients aged ≥12 years with an eosinophilic phenotype.
    Objectives: (1) Describe baseline demographic and clinical characteristics of new US adult mepolizumab users 2015-2019, (2) describe asthma medication use in the 12 months preceding initiation of and concomitant with mepolizumab and (3) assess mepolizumab adherence, persistence and discontinuation patterns in 12 months postinitiation.
    Methods: We conducted a new-user observational cohort study using data from Aetna, a CVS Health Company, HealthCore (Anthem), Harvard Pilgrim Healthcare, and IBM MarketScan Research Databases. Curated administrative claims data in the FDA Sentinel System common data model format and publicly available Sentinel analytical tools were used to query the databases. We included adults who initiated mepolizumab in 2015-2019 with an asthma diagnosis in the preceding 12 months and no evidence of cystic fibrosis. We examined age, sex, comorbid conditions, asthma medication use and severe asthma exacerbations.
    Results: We identified 3496 adults (mean age 54.2 years, SD 12.5 years) who initiated mepolizumab. In the 12 months before mepolizumab initiation, 22% had received inhaled corticosteroids, 46% had inhaled corticosteroid/long-acting beta agonists, 72.6% had leukotriene antagonists, 38% had long-acting muscarinic antagonist, 18% had omalizumab,<1% had reslizumab, dupilumab or benralizumab. In the previous 12 months, 70% had a diagnosis of allergic rhinitis, 32% had chronic obstructive pulmonary disease, 17% eosinophilia and 3% eosinophilic granulomatosis with polyangiitis. Further, 56% had an asthma-related ambulatory visit, 73%≥1 course of oral corticosteroids lasting 3-27 days, 10% an asthma-related emergency department visit and 22% an asthma-related hospitalisation. In the 12 months following initiation, the mean proportion of days covered was 70%, and reductions in the average mean dispensings of rescue oral corticosteriods (35%) and omalizumab (61%) were observed.
    Conclusions: Adults with asthma treated with mepolizumab had varying levels of healthcare utilisation and we observed evidence of mepolizumab use in patients without severe asthma.
    MeSH term(s) Adult ; Aged ; Anti-Asthmatic Agents/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Asthma/drug therapy ; Asthma/epidemiology ; Churg-Strauss Syndrome ; Granulomatosis with Polyangiitis ; Humans ; Middle Aged ; United States/epidemiology
    Chemical Substances Anti-Asthmatic Agents ; Antibodies, Monoclonal, Humanized ; mepolizumab (90Z2UF0E52)
    Language English
    Publishing date 2021-11-03
    Publishing country England
    Document type Journal Article ; Observational Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 2736454-9
    ISSN 2052-4439 ; 2052-4439
    ISSN (online) 2052-4439
    ISSN 2052-4439
    DOI 10.1136/bmjresp-2021-001003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Characteristics of new adult users of mepolizumab with asthma in the USA

    Pamela M McMahon / Ann Chen Wu / Emily Welch / Cheryl N McMahill-Walraven / Aziza Jamal-Allial / Mia Gallagher / Tancy Zhang / Christine Draper / Anne Marie Kline / Leslie Koerner / Jeffrey S Brown / Melissa K Van Dyke

    BMJ Open Respiratory Research, Vol 8, Iss

    2021  Volume 1

    Keywords Medicine ; R ; Diseases of the respiratory system ; RC705-779
    Language English
    Publishing date 2021-12-01T00:00:00Z
    Publisher BMJ Publishing Group
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  10. Article: Integration of Mobile Devices to Facilitate Patient Care and Teaching During Family-Centered Rounds.

    Byrd, Angela S / McMahon, Pamela M / Vath, Richard J / Bolton, Michael / Roy, Melissa

    Hospital pediatrics

    2017  Volume 8, Issue 1, Page(s) 44–48

    Abstract: Objectives: The increasing prevalence of mobile devices in clinical settings has the potential to improve both patient care and education. The benefits are particularly promising in the context of family-centered rounds in inpatient pediatric settings. ... ...

    Abstract Objectives: The increasing prevalence of mobile devices in clinical settings has the potential to improve both patient care and education. The benefits are particularly promising in the context of family-centered rounds in inpatient pediatric settings. We aimed to increase mobile device usage by inpatient rounding teams by 50% in 6 months. We hoped to demonstrate that use of mobile devices would improve access to patient care and educational information and to determine if use would improve efficiency and perceptions of clinical teaching.
    Methods: We designed a mixed-methods study involving pre- and post-implementation surveys to residents, families, and faculty as well as direct observations of family-centered rounds. We conducted rapid cycles of continual quality improvement by using the Plan-Do-Study-Act framework involving 3 interventions.
    Results: Pre-intervention, the mobile computing cart was used for resident education on average 3.3 times per rounding session. After cycle 3, teaching through the use of mobile devices increased by ∼79% to 5.9 times per rounding session. On the basis of survey data, we determined there was a statistically significant increase in residents' perception of feeling prepared for rounds, receiving teaching on clinical care, and ability to teach families. Additionally, average time spent per patient on rounds decreased after implementation of mobile devices.
    Conclusions: Integration of mobile devices into a pediatric hospital medicine teaching service can facilitate patient care and perception of resident teaching by extending the utility of electronic medical records in care decisions and by improving access to knowledge resources.
    MeSH term(s) Access to Information ; Computers, Handheld/statistics & numerical data ; Efficiency, Organizational ; Electronic Health Records ; Equipment and Supplies Utilization ; Family ; Hospitals, Pediatric/organization & administration ; Hospitals, Teaching/organization & administration ; Humans ; Internship and Residency ; Patient Care/methods ; Patient Education as Topic ; Point-of-Care Systems ; Quality Improvement ; Teaching Rounds/methods
    Language English
    Publishing date 2017-12-07
    Publishing country United States
    Document type Journal Article
    ISSN 2154-1663
    ISSN 2154-1663
    DOI 10.1542/hpeds.2016-0193
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top